Hydrolytic Cleavage of Optic Atrophy 1 Drives the Pathogenesis of CMT2A Neuropathy Caused by Mfn2 Mutation

Yuanzhu Zhang,Daxin Pang,Lerong Ma,Ziru Wang,Chuang Gao,Lin Yang,Mengjing Li,Xiaochun Tang,Hongming Yuan,Hongsheng Ouyang
DOI: https://doi.org/10.2139/ssrn.4081385
2022-01-01
Abstract:Background: Charcot-Marie-Tooth subtype 2A (CMT2A) is an autosomal dominant single-gene motor sensory neuropathy that is caused by mitofusin 2 (Mfn2) mutation. It is generally believed that CMT2A involves mitochondrial fusion disruption. However, how to ameliorate the loss of mitochondrial membrane fusion in CMT2A remains unclear. Methods: In vivo and in vitro mouse models harboring the Mfn2H165R, Mfn2G176S and Mfn2R364W mutations were constructed. We first examined mitochondrial damage and pathophysiological features of Mfn2 mutations. Then, we started with the proteins Mfn2 and Opa1 to analyze the mechanism of mitochondrial aggregation and fragmentation. Findings: Studies have shown that, in Mfn2R364W, Mfn2G176S, Mfn2H165R/+ mutations, fragmentation of mitochondria is mainly mediated by optic atrophy 1 (Opa1) hydrolytic cleavage rather than loss of Mfn2, as Mfn2 expression is activated by Bax translocation. While in Mfn2 H165R/H165R mutation, Opa1 hydrolytic cleavage and Mfn2 loss induced mitochondrial fragmentation and aggregation. Furthermore, in all mutations, hydrolytic cleavage of Opal is mediated by dissipation of mitochondrial membrane potential (MMP), apoptosis, and consequent uncoupling of oxidative phosphorylation. Interpretation: Mitochondrial aggregation and hydrolytic cleavage of Opa1 are two independent pathways of CMT2A pathogenesis: Opa1-induced mitochondrial fragmentation affects the stability of mitochondrial DNA and causes mitochondrial dysfunction, which ultimately leads to CMT2A; mitochondrial transport defect caused by loss of Mfn2 also contributes to the pathogenesis of CMT2A. Funding Information: This study was financially supported by a grant from the Special Funds for Cultivation and Breeding of New Transgenic Organisms (No. 2016ZX08006003), the Program for JLU Science and Technology Innovative Research Team (2017TD-28).Declaration of Interests: The authors declare no competing interest.Ethics Approval Statement: All animal studies were approved by the Animal Welfare and Research Ethics Committee of Jilin University, and all procedures were conducted in strict accordance with the Guide for the Care and Use of Laboratory Animals. The mice were euthanized at humane end-points or the predetermined end of the experiment. The animal carcasses were treated in a standardized and respectful manner after the experiment.
What problem does this paper attempt to address?